GH 10-K Annual Reports

Guardant Health, Inc. (GH) has filed its 10-K for the fiscal year ending December 31, 2025. The company reported total revenue of $982.0 million, a significant increase of 33% from the prior year, driven by strong growth in both its Oncology and Biopharma & Data segments. Despite this revenue growth, Guardant Health continued to incur substantial net losses, reporting a net loss of $416.3 million for the year, which is an improvement from the $436.4 million net loss in 2024. The company's expansion of its sales and marketing efforts, particularly for its Shield blood test for colorectal cancer screening, contributed to increased operating expenses, with sales and marketing expenses rising 36% year-over-year. Guardant Health remains focused on its strategic objectives of expanding clinical utility, increasing reimbursement, and strengthening customer relationships across its product portfolio, which spans therapy selection, minimal residual disease detection, and early cancer screening. Financially, the company ended the year with a strong cash position of approximately $1.3 billion in cash, cash equivalents, and marketable debt securities, providing ample runway. Key developments include the FDA approval and commercial availability of the Shield blood test for colorectal cancer screening, and continued investment in R&D to expand its technology platform. However, the company continues to face significant risks related to its profitability, ongoing losses, reimbursement uncertainties from payers, competitive pressures, and potential regulatory changes.

Guardant Health, Inc. (GH) presented its 2024 Annual Report on Form 10-K, highlighting significant revenue growth driven by its precision oncology testing business, which increased by 34% year-over-year to $687.9 million. This growth was fueled by a 34% rise in clinical testing revenue, attributed to increased sample volumes and improved reimbursement rates, particularly from Medicare for its Guardant360 LDT test. Biopharmaceutical revenue also saw a 31% increase. Despite top-line growth, the company continues to incur substantial net losses, with the 2024 net loss at $436.4 million, a slight improvement from $479.4 million in 2023. The company ended the year with a strong liquidity position, holding $944.2 million in cash, cash equivalents, restricted cash, and marketable debt securities, providing ample runway for continued investment in research and development, clinical studies, and commercial expansion. The company achieved a major milestone with the FDA approval and subsequent commercial launch of its Shield blood test for colorectal cancer screening in August 2024, making it the first FDA-approved blood test for primary colorectal cancer screening that also meets Medicare coverage requirements. This positions Guardant Health to address the critical early cancer detection market. Looking ahead, Guardant Health remains focused on expanding clinical utility, securing broader payer coverage and reimbursement, and growing its global commercial footprint. However, investors should remain aware of the significant risks outlined, including the ongoing unprofitability, dependence on reimbursement decisions, competitive pressures, and potential regulatory changes, particularly concerning Laboratory Developed Tests (LDTs).

Guardant Health, Inc. reported a total revenue of $563.9 million for the year ended December 31, 2023, a 25% increase year-over-year, driven primarily by a 31% rise in precision oncology testing revenue. Despite this top-line growth, the company continued to incur significant net losses, amounting to $479.4 million for the year. The company has a substantial cash and cash equivalents balance of $1.1 billion as of December 31, 2023, which it believes is sufficient to fund its operations for more than 12 months. The company is focused on expanding its product portfolio and market adoption, particularly with its Shield test for early cancer detection, for which a PMA was submitted to the FDA. However, significant risks remain, including the company's ongoing unprofitability, dependence on third-party payer coverage and reimbursement, and intense competition in the precision oncology market. A recent jury verdict in a patent infringement case resulted in an $83.4 million liability accrual, which is a significant concern for investors.

Guardant Health, Inc. (GH) presented its 2022 Form 10-K filing, highlighting significant revenue growth driven by its precision oncology testing services, which increased by 29% year-over-year to $392 million. Despite this growth, the company continues to incur substantial net losses, with a reported net loss of $654.6 million for the year, indicating ongoing investments in research and development and commercial expansion. The company's core strategy revolves around expanding the clinical utility and reimbursement of its liquid biopsy tests across all cancer stages, from early detection to recurrence monitoring. Key product launches and study results, such as the positive efficacy data from the ECLIPSE study for its Shield blood test for colorectal cancer screening, underscore the company's commitment to innovation. However, significant risks remain, including continued operational losses, intense competition, and ongoing regulatory scrutiny, particularly concerning laboratory-developed tests (LDTs) and reimbursement policies from third-party payers.

Guardant Health, Inc. (GH) reported a strong increase in total revenue for the year ended December 31, 2021, reaching $373.7 million, a 30% increase from the prior year. This growth was driven primarily by a 29% increase in precision oncology testing revenue, which reached $304.3 million, fueled by higher sample volumes and an improved average selling price for certain tests. The company also saw a significant 38% increase in development services and other revenue, primarily from companion diagnostic development services and milestone payments. Despite revenue growth, Guardant Health continued to incur substantial net losses, with a loss of $384.8 million for 2021, compared to $246.3 million in 2020. This widening loss reflects significant investments in research and development (up 76% to $263.2 million) and sales and marketing (up 80% to $191.9 million) to support product development, clinical studies, and commercial expansion. The company ended the year with a substantial cash and cash equivalents and marketable securities balance of approximately $1.6 billion, providing ample runway for ongoing operations and strategic investments.

Guardant Health, Inc.'s (GH) 10-K filing for the fiscal year ended December 31, 2020, highlights the company's operational and financial status as it continues to advance its precision oncology testing and development services. The company operates as a single reportable segment, indicating a unified business strategy. A significant portion of its financial assets are held in cash equivalents and marketable securities, providing a stable liquidity position. The filing details Guardant Health's revenue recognition policies under ASC 606, emphasizing the complexities in estimating variable consideration for clinical tests and milestone-based revenue for biopharmaceutical services. The company also discloses substantial investments in research and development, along with a significant increase in stock-based compensation, particularly related to market-based restricted stock units (MSUs) for executive compensation. The issuance of $1.15 billion in 0% Convertible Senior Notes in November 2020 is a key event, intended to fund operations and future growth, alongside hedging transactions to mitigate potential dilution. Financially, the company reported a net loss for the year, a common characteristic of growth-stage biotechnology companies investing heavily in innovation and market expansion. Key areas of focus for investors include the company's strong liquidity, ongoing investment in R&D, the strategic implications of its joint venture, and the potential impact of its convertible debt and stock-based compensation on future earnings and shareholder value.

Guardant Health, Inc.'s 2019 10-K filing, as of March 2, 2020, highlights a company in a significant growth phase within the precision oncology market. The company is focused on developing and commercializing advanced cancer diagnostics, particularly through its liquid biopsy technologies. Investors should note the substantial investment in research and development (R&D) and sales and marketing as key drivers for future revenue generation, indicating a strategic emphasis on market penetration and product innovation. While revenue growth is evident, the company continues to operate at a net loss, which is typical for companies in this R&D-intensive sector. The filing underscores the potential for Guardant's technology to transform cancer detection and treatment, but also points to inherent risks related to clinical validation, regulatory approvals, market adoption, and competition.

Guardant Health, Inc. (GH) filed its 2018 10-K on March 19, 2019, detailing its financial performance and strategic initiatives. The company, a leader in precision oncology, reported significant revenue growth, driven by its Guardant360 and GuardantOMNI liquid biopsy tests. Total revenue for 2018 reached $90.6 million, an 82% increase from the prior year, reflecting strong adoption among both clinical and biopharmaceutical customers. Despite revenue growth, Guardant Health continued to incur substantial net losses, totaling $84.3 million in 2018, a slight increase from $83.2 million in 2017. This is attributed to significant investments in research and development, sales and marketing, and general administrative expenses, reflecting the company's strategy to drive innovation and market penetration. The company's strong cash position, bolstered by a successful IPO in October 2018, provides ample runway to fund operations and future growth initiatives. Management believes current cash reserves are sufficient for at least the next 12 months, though they may seek additional capital to fund expansion or strategic investments.